- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02171533
Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers
Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages (240 mg and 480 mg Daily) (Open-label, Fixed-sequence Design), and Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate Given With or Without Single Oral Doses of 120 mg (IR) or 240 mg (ER) of Verapamil Administered at Different Time Points Relative to Dabigatran Etexilate Dosing in Healthy Male and Female Volunteers (Open-label, Randomised, Five-way Crossover Design, Phase I Study)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria:
- Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests
- Age ≥18 and ≤55 years
- Body mass index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
- Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation
Exclusion criteria:
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Relevant surgery of gastrointestinal tract
- History of any bleeding disorder or acute blood coagulation defect
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Pulse rate below 50 bpm and or systolic blood pressure <90 mm Hg at screening. ECG: PR >170 ms (Part 1), AV block ≥1st degree (Part 2) at screening
- Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within four weeks prior to administration or during the trial, especially intake of medication, which influences the blood clotting, i.e., acetylsalicylic acid, cumarin etc.
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (more than 15 cigarettes or 3 cigars or 3 pipes per day)
- Alcohol abuse (more than 60 g/day for men and more than 40 g/day for women)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Planned surgeries within four weeks following the end-of study examination
The subject is not able to understand and comply with protocol requirements, instructions, protocol-stated restrictions and dietary regimen of study centre
For male subjects:
Male subjects who do not agree to minimise the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the post study medical. Acceptable methods of contraception comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two month)
For female subjects:
- Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion
- No adequate contraception during the study and until 1 month of study completion, i.e. implants, injectables, combined oral contraceptives, IUD (intrauterine device), sexual abstinence (for at least 1 month prior to enrolment), vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (incl. hysterectomy). Females, who have not a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to additionally use barrier contraception methods (e.g. condom, diaphragm with spermicide)
- Lactation period
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Fixed sequence
Treatments will be given in a fixed sequence
|
|
Expérimental: Crossover
Treatments will be given in randomized sequences
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
AUC0-infinity (area under the concentration-time curve of total dabigatran over the time interval from 0 extrapolated to infinity)
Délai: up to 107 hours
|
up to 107 hours
|
Cmax (maximum measured concentration of total dabigatran)
Délai: up to 107 hours
|
up to 107 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
AUC0-infinity (area under the concentration-time curve of free dabigatran over the time interval from 0 extrapolated to infinity)
Délai: up to 107 hours
|
up to 107 hours
|
|
Cmax (maximum measured concentration of free dabigatran)
Délai: up to 107 hours
|
up to 107 hours
|
|
AUC0-infinity (area under the concentration-time curve of verapamil over the time interval from 0 extrapolated to infinity)
Délai: up to 107 hours
|
up to 107 hours
|
|
Cmax (maximum measured concentration of verapamil)
Délai: up to 107 hours
|
up to 107 hours
|
|
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
Délai: up to 107 hours
|
up to 107 hours
|
|
AUC0-24 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 h after the administration)
Délai: up to 107 hours
|
up to 107 hours
|
|
tmax (time from dosing to the maximum concentration of the analyte in plasma)
Délai: up to 107 hours
|
up to 107 hours
|
|
λz (terminal rate constant in plasma)
Délai: up to 107 hours
|
up to 107 hours
|
|
t1/2 (terminal half-life of the analyte in plasma)
Délai: up to 107 hours
|
up to 107 hours
|
|
MRTpo (mean residence time of the analyte in the body after oral administration)
Délai: up to 107 hours
|
up to 107 hours
|
|
CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
Délai: up to 107 hours
|
up to 107 hours
|
|
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Délai: up to 107 hours
|
up to 107 hours
|
|
AUCτ,ss (area under the concentration-time curve of verapamil within the uniform dosing interval τ)
Délai: up to 107 hours
|
up to 107 hours
|
|
AUC0-tz,ss (area under the concentration-time curve of verapamil from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)
Délai: up to 107 hours
|
up to 107 hours
|
|
Cmax,ss (maximum concentration of verapamil at steady state)
Délai: up to 107 hours
|
up to 107 hours
|
|
tz,ss (time of last measureable concentration of verapamil within the dosing interval τ at steady state)
Délai: up to 107 hours
|
up to 107 hours
|
|
tmax,ss (time from last dosing to the maximum concentration of verapamil at steady state on day 4)
Délai: up to 107 hours
|
up to 107 hours
|
|
CL/F,ss (apparent clearance of verapamil at steady state after extravascular multiple dose administration)
Délai: up to 107 hours
|
up to 107 hours
|
|
Cmin,ss (minimum measured concentration of verapamil at steady state over a uniform dosing interval τ)
Délai: up to 107 hours
|
up to 107 hours
|
|
tmin,ss (time from last dosing to the minimum concentration of verapamil at steady state over a uniform dosing interval τ)
Délai: up to 107 hours
|
up to 107 hours
|
|
Cpre,ss (predose concentration of verapamil at steady state immediately before administration of the next dose)
Délai: up to 107 hours
|
up to 107 hours
|
|
Cavg (Average concentration of verapamil at steady state)
Délai: up to 107 hours
|
up to 107 hours
|
|
MRTpo,ss (mean residence time of verapamil in the body at steady state after oral administration)
Délai: up to 107 hours
|
up to 107 hours
|
|
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration)
Délai: up to 107 hours
|
up to 107 hours
|
|
Ae0-24 (amount of dabigatran that is eliminated in urine from the time interval 0-24h)
Délai: up to 107 hours
|
up to 107 hours
|
|
fe0-24 (fraction of administered drug excreted unchanged in urine from time point 0- 24h)
Délai: up to 107 hours
|
up to 107 hours
|
|
CLR0-24 (renal clearance of dabigatran from the time point 0 until the time point 24h )
Délai: up to 107 hours
|
up to 107 hours
|
|
AUEC0-24 (area under the effect curve)
Délai: up to 107 hours
|
for ecarin clotting time and thrombin time
|
up to 107 hours
|
ERmax (maximum effect ratio)
Délai: up to 107 hours
|
for ecarin clotting time and thrombin time
|
up to 107 hours
|
Occurence of Adverse Events
Délai: within 5 days after last drug administration
|
within 5 days after last drug administration
|
|
Assessment of Tolerability by investigator
Délai: within 5 days after last drug administration
|
within 5 days after last drug administration
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-arythmie
- Agents vasodilatateurs
- Inhibiteurs d'enzymes
- Inhibiteurs de protéase
- Modulateurs de transport membranaire
- Hormones et agents régulateurs du calcium
- Antithrombines
- Inhibiteurs de la sérine protéinase
- Anticoagulants
- Bloqueurs de canaux calciques
- Dabigatran
- Vérapamil
Autres numéros d'identification d'étude
- 1160.74
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur En bonne santé
-
AstraZenecaParexelComplété